India grants first ever compulsory license - for Bayer's Nexavar
This article was originally published in Scrip
India has now granted its first-ever compulsory licence in medicines with the issuing of an order that gives the Indian generics and biosimilar producer Natco the right to produce and market a version of Bayer's anticancer, Nexavar (sorafenib tosylate), in India.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.